Works matching Bristol-Myers Co.
1
- Berkeley Technology Law Journal, 2005, v. 20, n. 1, p. 174
- Article
2
- American University Law Review, 2023, v. 73, n. 1, p. 293
- Article
3
- Mississippi College Law Review, 2019, v. 37, n. 3, p. 245
- Article
4
- Maryland Law Review, 2018, v. 77, n. 3, p. 862
- Article
5
- Angewandte Chemie, 2004, v. 116, n. 10, p. 1290
- Joseph M. Ready;
- Sarah E. Reisman;
- Makoto Hirata;
- Matthew M. Weiss;
- Kazuhiko Tamaki;
- Timo V. Ovaska;
- John L. Wood
- Article
6
- Angewandte Chemie International Edition, 2004, v. 43, n. 10, p. 1270, doi. 10.1002/anie.200353282
- Joseph M. Ready;
- Sarah E. Reisman;
- Makoto Hirata;
- Matthew M. Weiss;
- Kazuhiko Tamaki;
- Timo V. Ovaska;
- John L. Wood
- Article
7
- University of Cincinnati Law Review, 2018, v. 87, n. 3, p. 829
- Article
8
- Bulletin of the World Health Organization, 2015, v. 93, n. 11, p. 799, doi. 10.2471/BLT.15.157784
- Edwards, Danny J.;
- Coppens, Delphi G. M.;
- Prasad, Tara L.;
- Rook, Laurien A.;
- Iyera, Jayasree K.
- Article
9
- Hawaii Journal of Medicine & Public Health, 2013, v. 72, n. 1, p. 34
- Article
10
- Diabetes, Obesity & Metabolism, 2014, v. 16, n. 3, p. 286, doi. 10.1111/dom.12265
- Article
11
- 2003
- Lilienfeld, David E.;
- Nicholas, Savian;
- Macneil, Daniel J.;
- Kurjatkin, Olga;
- Gelardin, Thomas;
- Lilienfeld, David;
- Macneil, Daniel
- commentary
12
- Nature Biotechnology, 2005, v. 23, n. 11, p. 1323, doi. 10.1038/nbt1105-1323
- Article
13
- Nature Biotechnology, 2005, v. 23, n. 2, p. 249, doi. 10.1038/nbt0205-249
- Article
14
- Nature Biotechnology, 2002, v. 20, n. 12, p. 1181
- Article
15
- Nature Biotechnology, 1999, v. 17, n. 3, p. 212, doi. 10.1038/6923
- Article
16
- Clinical Infectious Diseases, 2005, v. 40, n. 10, p. 1
- Article
17
- Clinical Infectious Diseases, 2005, v. 40, n. 2, p. 1
- Article
18
- Clinical Infectious Diseases, 2004, v. 39, n. 1, p. iv
- Article
19
- Alabama Law Review, 2022, v. 73, n. 3, p. 583
- Article
20
- Berkeley Technology Law Journal, 2016, v. 31, p. 587, doi. 10.15779/Z38C85X
- Article
21
- Berkeley Technology Law Journal, 2002, v. 17, n. 1, p. 155
- Article
24
- Australian Prescriber, 2011, v. 34, n. 3, p. 89
- Article
25
- Nature, 2007, v. 447, n. 7148, p. 1045, doi. 10.1038/4471045a
- Article
26
- Nature, 2007, v. 446, n. 7131, p. 15, doi. 10.1038/446015a
- Article
27
- Defense Counsel Journal, 2018, v. 85, n. 2, p. 1
- Mellow, Mary Anne;
- Walsh, Steven T.;
- Tevlin, Timothy R.
- Article
28
- Defense Counsel Journal, 2018, v. 85, n. 1, p. 1
- Prost, Mark A.;
- Walsh, Steve
- Article
29
- Defense Counsel Journal, 2018, v. 85, n. 1, p. 1
- Boschert, Neville H.;
- Harris, Andrew S.
- Article
30
- Expert Review of Neurotherapeutics, 2008, v. 8, n. 1, p. 7
- Article
31
- Nursing Education Perspectives (National League for Nursing), 2005, v. 26, n. 5, p. 322
- Article
34
- Formulary, 2008, v. 43, n. 6, p. 189
- Article
36
- Formulary, 2007, v. 42, n. 6, p. 362
- Article
38
- Formulary, 2003, v. 38, n. 8, p. 455
- Article
39
- Formulary, 2000, v. 35, n. 10, p. 32
- Article
40
- Formulary, 1997, v. 32, n. 10, p. 1011
- Article
41
- Nephrology, 2006, v. 11, p. iv, doi. 10.1111/j.1440-1797.2006.00658_3.x
- Article
42
- Journal of Pharmacy & Bioallied Sciences, 2011, v. 3, n. 4, p. 546, doi. 10.4103/0975-7406.90113
- Patel, Vishal;
- Gandhi, Hardik;
- Upaganlawar, Aman
- Article
43
- Applied Clinical Trials, 2005, v. 14, n. 9, p. 68
- Article
45
- Australian Journal of Pharmacy, 2011, v. 92, n. 1096, p. 56
- Article
46
- Journal of Generic Medicines, 2005, v. 3, n. 1, p. 85, doi. 10.1057/palgrave.jgm.4940103
- Article
47
- Brown University Psychopharmacology Update, 2005, v. 16, n. 4, p. 8
- Article
48
- Brown University Psychopharmacology Update, 2004, v. 15, n. 11, p. 8
- Article
49
- Brown University Psychopharmacology Update, 2003, v. 14, n. 3, p. 7
- Article
50
- Brown University Psychopharmacology Update, 2002, v. 13, n. 1, p. 8
- Article